Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective
Sonnet BioTherapeutics 表示,来自化疗诱发的周围神经病变的 SON-080 1b/2a 期临床试验的早期安全数据符合研究最初的预先设定目标